Skip to main content
Jongsoo Lee on Muck Rack

Jongsoo Lee

New York
As seen in: Financial Times, Newsweek Europe, PLOS ONE, Business Wire, MDPI, The Diplomat Magazine, The National Interest, NewsBreak, 38 North, Tribune Content Agency and

Get in touch with Jongsoo

Contact Jongsoo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models Original

|
By Jongsoo Lee
| Business Wire
Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models SEOUL, South Korea--(BUSINESS WIRE)--Genexine, Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company, today announced new preclinical data for its SOX2-targeting bioPROTAC candidate, GX-BP1, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego.
Open in Who Shared View Duplicates (20) Issue with article?

Correction: Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data

|
By Jongsoo Lee, Miho Song, Subeen Leem, Jong-Yeup Kim
| PLOS ONE
The fifth to seventh authors are listed out of order. Please view the correct author order, affiliations, and citation here: Jongsoo Lee 1, Miho Song 2, Subeen Leem 3, Jong-Yeup Kim 3–5 Sung Ryul Shim 3,4, Jae Heon Kim 2, Benjamin I.
Open in Who Shared Issue with article?

Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data

|
By Jongsoo Lee, Yonsei College, Miho Song, Soonchunhyang College
| PLOS ONE
Discussion Our study provides important insight that we analyzed real word database and evaluated comparative drug safety across all type of prostate cancer. Although we could not make a conclusion whether which is the safest ARPI for prostate cancer, we can suggest that each ARPIs have different types of AEs hence we can use this information during choosing ARPIs for prostate cancer patients.
Open in Who Shared Issue with article?
See all 37 licensed articles (40 Total)